(Q43986541)

28 November 2017

title

Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth (English)

1 reference

28 November 2017

0 references

1 reference

1 reference

11

1 reference

28 November 2017

13

Carole A Long

1 reference

28 November 2017

6

Keith Limbach

1 reference

28 November 2017

3

Noelle B Patterson

1 reference

28 November 2017

14

Denise L Doolan

1 reference

28 November 2017

12

C Richter King

1 reference

28 November 2017

Joseph T Bruder

1

1 reference

28 November 2017

Maureen E Stefaniak

2

1 reference

28 November 2017

Ping Chen

4

1 reference

28 November 2017

Svetlana Konovalova

5

1 reference

28 November 2017

Joseph J Campo

7

1 reference

28 November 2017

Damodar Ettyreddy

8

1 reference

28 November 2017

Sheng Li

9

1 reference

28 November 2017

Filip Dubovsky

10

1 reference

28 November 2017

language of work or name

English

0 references

publication date

25 February 2010

1 reference

28 November 2017

1 reference

28 November 2017

volume

28

1 reference

28 November 2017

issue

18

1 reference

28 November 2017

page(s)

3201-3210

1 reference

Gamma-globulin and acquired immunity to human malaria

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Apical membrane antigen 1: a malaria vaccine candidate in review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Biosynthesis of a putative protective Plasmodium knowlesi merozoite antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Specificity of the protective antibody response to apical membrane antigen 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Malaria sporozoite: migrating for a living

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Immunization against blood-stage rodent malaria using purified parasite antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Effective induction of high-titer antibodies by viral vector vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Immune response to pre-erythrocytic stages of malaria parasites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

T-cell activation through immunological synapses and kinapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Protein glycosylation in the malaria parasite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Analysis of recombinant merozoite surface protein-1 of Plasmodium falciparum expressed in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Molecular basis of the inflammatory response to adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.024

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.02.024

1 reference

28 November 2017

1 reference